Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study.

Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study.

Publication date: Sep 16, 2024

The WHO estimates a gap of about 30% between the incident (10. 6 million) and notified (7. 5 million) cases of tuberculosis (TB). Combined with the growing recognition in prevalence surveys of the high proportion of cases identified who are asymptomatic or paucisymptomatic, these data underscore how current symptom screening approaches and use of diagnostic tests with suboptimal performance on sputum miss large numbers of cases. Thus, the development of sputum-free biomarker-based tests for diagnosis is becoming necessary, which the WHO has already identified as a priority for new TB diagnostics. The objective of this study is to evaluate a combination of exhaled breath condensate (EBC) samples and mycobacterial lipoarabinomannan (LAM) as point-of-care (POC) assays to identify TB patients. This prospective diagnostic accuracy study is conducted at the TB Screening and Treatment Centre of International Center for Diarrhoeal Disease Research, Bangladesh, on a cohort of adults and adolescents >11 years of age. A total of 614 individuals with presumptive pulmonary TB based on TB signs, symptoms and radiography are being recruited from 28 August 2023. Spot sputum is collected for standard reference testing (L-J culture, GeneXpert MTB/Rif, acid-fast Bacilli microscopy) to fine-tune categorisation of TB disease status for each participant, defined as (1) definite TB (at least one positive standard reference test); (2) probable TB (not microbiologically confirmed but under TB treatment); (3) possible TB (no TB treatment but signs, symptoms and radiography suggestive of TB); (4) other respiratory disease (microbiologically not confirmed and no radiography presenting abnormalities compatible with TB); and (5) unknown (no microbiological evidence with normal/no TB abnormalities with radiography). Urine and EBC specimens will be subjected to LAM POC testing and biobanked for further investigation. Statistical analyses will include an assessment of diagnostic accuracy by constructing receiver operating curves and calculating sensitivity and specificity, as well as post-test probabilities. The study protocol was approved by the Research Review Committee as well as the Ethical Review Committee of icddr,b and recorded under a protocol reference number, PR-2301. Results will be submitted to open-access peer-reviewed journals, presented at academic meetings, and shared with national and international policymaking bodies.

Open Access PDF

Concepts Keywords
6million Adolescent
August Adult
Bangladesh Bangladesh
Policymaking Biomarkers
Tuberculosis Biomarkers
Breath Tests
Diagnostic microbiology
Female
Humans
lipoarabinomannan
Lipopolysaccharides
Lipopolysaccharides
Male
Mycobacterium tuberculosis
Point-of-Care Systems
Point-of-Care Testing
Prospective Studies
Pulmonary Disease
Sensitivity and Specificity
Sputum
Tuberculosis
Tuberculosis, Pulmonary

Semantics

Type Source Name
disease IDO assay
disease MESH pulmonary tuberculosis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO symptom
disease MESH abnormalities
disease MESH inflammation
drug DRUGBANK Medical air
drug DRUGBANK Coenzyme M
disease MESH morbidity
disease IDO host
disease IDO blood
drug DRUGBANK Water
disease MESH infections
disease IDO infection
pathway REACTOME Metabolism
pathway REACTOME Fatty acids
disease IDO history
disease IDO facility
disease IDO country
drug DRUGBANK Trestolone
disease IDO process
disease MESH weight loss
disease MESH cognitive impairment
disease MESH mental illness
drug DRUGBANK Aluminium
drug DRUGBANK Gold
disease MESH Pulmonary Disease

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *